Intelligence · Clinical Development
Pipeline search results
Programs matching “control” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 67 pipeline programs matching "control" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
AL8326
Lacuna Pharma Pty Ltd
- Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment., - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment.
1 trial -
AL8326
Lacuna Pharma Pty Ltd
Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage., Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.
1 trial -
CMAS825D12201
Novartis Pharmaceuticals
Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.
1 trial -
D6830C00003
AstraZeneca AB
Asthma in adults who remain uncontrolled despite medium to high dose ICS plus LABA, and who are at risk of exacerbations.
1 trial -
D7552C00001
AstraZeneca AB
Moderate-to-Severe Uncontrolled Asthma
1 trial -
D8210C00003
AstraZeneca AB
Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
1 trial -
EnEPC-CLI-01
Biogen
Peripherial arterial disease (PAD) & Chronic-Limb Threatening Ischemia (CLTI) patients who have not responded to standard pharmacological treatment or control of risk factors, and/or had a revascularisation with continued presence of smaller vessel (microvasculature) disease, and do not have the option of a revascularization treatment.
1 trial -
Experimental: CHF6001 3200 μg
Chiesi Farmaceutici S.p.A.
Uncontrolled Asthma
1 trial -
INCB 54707-208
Incyte
Treatment of patients with inadequately controlled moderate to severe asthma
1 trial -
KPL-387
Kiniksa Pharmaceuticals International, plc
Well-Controlled Recurrent Pericarditis
1 trial -
KT621-AS-202
Kymera Therapeutics
Uncontrolled Moderate to Severe Eosinophilic Asthma
1 trial -
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
RELMADA THERAPEUTICS, INC.
Non Muscle Invasive Bladder Cancer
1 trial -
REGN5381
Regeneron UK Limited
Uncontrolled Hypertension
1 trial -
Target-controlled naloxone-infusion
BRIGHT MINDS BIOSCIENCES INC.
Central Nervous System Sensitization
1 trial -
UC-BCG-2312
Ningbo Cancer Hospital
Patients with HER2-positive locally advanced inoperable or metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy
1 trial -
controlled release carvedilol
BRIGHT MINDS BIOSCIENCES INC.
Cocaine Dependence
1 trial -
01-DAP-BIO-24
Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
intended for treatment of for the treatment of (2): • insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. • symptomatic chronic heart failure. • chronic kidney disease.
1 trial -
22534
Bayer AG
Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.
1 trial -
A randomized double-blind placebo-controlled... for Circulatory shock
Lacuna Pharma Pty Ltd
Circulatory shock
1 trial -
A trial to learn how baxdrostat affects the heartbeat in healthy participants
AstraZeneca AB
Treatment-resistant hypertension, Primary aldosteronism, Uncontrolled hypertension
1 trial -
AN OPEN-LABEL for Intramuscular administration of…
Lacuna Pharma Pty Ltd
Intramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.
1 trial -
Control Group
Tvardi Therapeutics
Squamous Cell Carcinoma of Head and Neck
1 trial -
JSVCT098
Jiangsu Province Centers for Disease Control and Prevention
COVID-19
1 trial -
Placebo pills for 14-day intervention
BRIGHT MINDS BIOSCIENCES INC.
Healthy Controls
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.